Agreement expands Mycovia’s worldwide commercialization plans for VT-1161 to European countries, Latin America, Australia, Russia and Commonwealth of Independent States
Mycovia continues to quickly develop VT-1161 as a possible first FDA-approved remedy for recurrent candidiasis that is vulvovaginal
DURHAM, N.C.–( COMPANY WIRE )–Mycovia Pharmaceuticals, Inc. today announced it offers entered into a special permit and development and technology transfer contract with Gedeon Richter Plc., situated in Budapest, Hungary, to commercialize and manufacture VT-1161 in European countries, Latin America, Australia, Russia along with other CIS nations. VT-1161, an dental product that is antifungal, is in period 3 medical studies for the remedy for Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that impacts almost 138 million ladies global every year.
“We are excited to partner with Gedeon Richter, an organization with strong market leadership in women’s health, to build up and commercialize VT-1161, our possible first treatment that is FDA-approved RVVC,” said Patrick Jordan, CEO of Mycovia and Partner at NovaQuest Capital Management, which formed Mycovia in 2018 to advance VT-1161 in worldwide areas. “Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand”の続きを読む